Oct 2026
Cardiovascular risk associated with first-line Janus kinase inhibitors versus TNF inhibitors in patients with RA: a nationwide cohort study.
First-line use of JAKi was not associated with an increased risk of MACE compared with TNFi, providing real-world evidence supporting the cardiovascular safety of JAKi as first-line advanced therapy in patients with RA.
O. C. Kwon, Hye Sun Lee, S. Jeon et al.
· Rheumatology · 0 citations